NewLink Genetics

NLNK NASDAQ
1.610
+0.050
+3.21%
盘后: 1.600 -0.01 -0.62% 16:00 07/19 EDT
开盘
1.550
昨收
1.560
最高
1.670
最低
1.520
成交量
48.32万
成交均量(3M)
38.45万
52周最高
4.800
52周最低
1.278
换手率
1.30%
市值
6,001.45万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供NewLink Genetics NLNK股票价格,NewLink Genetics股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.
展开 >

最近浏览

名称
价格
涨跌幅